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http://dx.doi.org/10.1016/j.pedneo.2Asthma is the most common chronic lower respiratory tract disease in childhood throughout
the world. Despite advances in asthma management, acute exacerbations continue to be a ma-
jor problem in patients and they result in a considerable burden on direct/indirect health care
providers. A severe exacerbation occurring within 1 year is an independent risk factor. Respi-
ratory tract viruses have emerged as the most frequent triggers of exacerbations in children. It
is becoming increasingly clear that interactions may exist between viruses and other triggers,
increasing the likelihood of an exacerbation. In this study, we provide an overview of current
knowledge about asthma exacerbations, including its definition, impact on health care pro-
viders, and associated factors. Prevention management in intermittent asthma as well as inter-
mittent wheeze in pre-school children and those with persistent asthma are discussed. Our
review findings support the importance of controlling persistent asthma, as indicated in cur-
rent guidelines. In addition, we found that early episodic intervention appeared to be crucial
in preventing severe attacks and future exacerbations. Besides the use of medication, timely
education after an exacerbation along with a comprehensive plan in follow up is also vitally
important.
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Asthma is the most common pediatric chronic respiratory
disease, affecting 7.4% of children in central Taiwan,1
19.7% in northern Taiwan,2 and up to 32.6% in the West-
ern world.3
Exacerbation is a component of asthma that has a sig-
nificant impact on both the child and the child’s family. An
exacerbation is often the initial event that precedes diag-
nosis of this disease and constitutes the majority of acute
care events in children.4 Despite advances in asthma
management and the introduction of guidelines specifically
for pediatric asthma, acute exacerbations continue to
occur and impose considerable morbidity on pediatric pa-
tients, thereby placing a considerable strain on health care
resources as well as on the lives of affected children and
their families.5
In the Asia-Pacific region, a survey conducted in 20066
showed persistently poor control in asthmatic children.
Compared with the results of a survey conducted in 2000,7
there has been no subsequent decrease in urgent care due
to asthma exacerbation (44% in 2000 vs. 43% in 2006),
including emergency department (ED) visits (19% vs. 19%),
and hospitalization (15% vs. 17%). The urgent care rate in
asthma patients may be as high as 43%. Real-world surveys
conducted in the USA and Europe also revealed a consid-
erable burden on patients and health care providers asso-
ciated with asthma exacerbation.8,9
Current guidelines assess asthma control based on two
main facets: clinical control and future risk.10 The presence
of an exacerbation has been shown to be equal to impair-
ment in assessing the level of control. However, the two
domains are not necessarily concordant. Patients may be
well controlled in the impairment domain and be receiving
optimal medications, yet still experience a severe exacer-
bation.11e13 The current interest in this aspect of asthma is
reflected in numerous recent publications examining ex-
acerbations from various points of view. Furthermore, the
International Collaboration in Asthma, Allergy and Immu-
nology (iCAALL), recently formed by the EAACI, AAAAI,
ACAAI, and WAO, has proposed an International Consensus
on (ICON) Pediatric Asthma in 201214 and emphasizes the
management of exacerbations to be a major consideration,
independent of chronic treatment. iCAALL considers
“improved asthma exacerbation treatment” to be “an
important unmet need”; and thus recommends undertaking
core research with a view to developing “new medication
and/or strategies.” The aim of the present study was to
provide a review of recent reports on clinical practicability
in asthma/wheeze exacerbation, with a particular
emphasis on investigations highlighting findings that have
not yet been fully discussed in the present guidelines (Table
1). Recent research on novel therapeutic modalities is not
included in this review.
2. Definition of Asthma Exacerbation
Asthma exacerbation, also termed asthma “attack” or
“episode”, is a very common condition in pediatric prac-
tice. Although a detailed assessment of severity and
treatment for exacerbation was first proposed in guidelinesmany years ago, the definition of asthma exacerbation re-
mains controversial.14,15 In the most recently published
consensus in pediatric asthma in 2013, asthma exacerbation
was defined as an acute or subacute episode of progressive
increase in asthma symptoms, associated with airflow
obstruction.14 The most commonly included exacerbation
outcomes are the need for systemic corticosteroids, urgent
unscheduled care, emergency department (ED) or urgent
care (UC) visits, and hospitalizations for asthma.15
In young children, recurrent wheezing is a challenge in
asthma diagnosis. In the PRACTALL consensus report pub-
lished in 2008,16 the “phenotypes” of “persistent
wheezing”, ”intermittent severe wheezing”, and “non-
atopic wheezing (mainly triggered by virus infection)” were
proposed. These three phenotypes are very similar to
asthma exacerbation in young children. It is difficult to
diagnose asthma in young children and infancy; however,
several publications have yielded useful finding, on pre-
vention of severe wheezing attack and future wheezing in
this age group, especially those with high asthma prediction
index (API). These publications are discussed later in this
review.
3. Burden in Asthma Exacerbation
In the United States in 2007, there were 0.64 million
asthma-related ED visits by children and 157,000 asthma-
related pediatric hospitalizations.17 A survey of 753 chil-
dren with asthma in seven European countries revealed
that 36% of children required an unscheduled urgent care
visit in the past 12 months. Eighteen percent of children
required one or more ED visits due to asthma in the past
year.9 In the Asia-Pacific area, unscheduled care (UC) costs
were responsible for 18e90% of total per-patient direct
costs. Overall, total per-patient direct costs were equiva-
lent to 13% of per capita gross domestic product and 300%
of per capita healthcare spending,18 which do not include
indirect social/economic costs. In Taiwan, the percentages
of hospitalizations and ED visits for asthma patients were
estimated to be 12% and 25% per year, respectively, which
is equivalent to 1.2 in-patient days and 0.59 ED visits per
patient per year, respectively.18 An analysis of data
collected from Taiwan’s National Health Insurance
Research database in 2002 showed that overall health
expenditure in pediatric asthma patients was 2.2 times
higher than that in patients without asthma, and one-fourth
of the cost for asthmatic children was attributed to hospi-
talization and UC.19
4. Factors Associated with Exacerbations
4.1. Poor asthma control
Poor asthma control can lead to severe asthma exacerba-
tions.20 In a study from the National Heart, Lung, and Blood
Institute’s Severe Asthma Research Program, the percent-
age of asthmatic patients with three or more exacerbations
per year was 5% in the mild group, 13% in the moderate
group, and 54% in the severe group, suggesting that
frequent exacerbations are related to disease severity.21 In
Table 1 Summary of studies for asthma exacerbation prevention.
Reference number
(publication year)
Age (year) Intervention ER visit Corticosteroid
usage
Social: school absence,
parents’ work
Prevent future
attack
Others
Intermittent asthma (wheezing)
47 (2005) 2e5 Daily montelukast for 12 mo Decrease Decrease ICS
usage
NA Prolong the
time to next
exacerbation
48 (2007) 2e14 Short course of montelukast
for at least 7 d, determined by
parents. Study period: 1 y
Decrease No decrease in
systemic usage
Decreased NA No decrease in
hospitalization
49 (2008) 1e6 Early use of ICS or montelukast
in URI for 7 d Study period: 1 y
No decrease No decrease in
oral usage
Not decreased No effect No difference in
linear growth
compare to
placebo group
50 (2009) 1e6 Fluticasone 750 mg bid from URI
onset. Maximum: 10 d Study
period: 6e12 mo
NA Decrease
systemic use
NA NA Smaller linear
growth
51 (2003) 1e4.5 Budesonide 1 mg bid from early
URI for 7 d Study period: 1 y
No difference
to daily
budesonide
use
Decrease total
budesonide usage
Similar asthma
control as daily
budesonide
Similar to daily
budesonide
usage
52 (2009) <17 Intermittent ICS in early URI No decrease No decrease NA, but parents
preferred this
management.
NA Cochrane
meta-analysis
53 (2009) 0.8e5 Prednisolone 10 mg or 20 mg
qd from 1st d of admission
NA No decrease in
hospital day.
NA NA No difference
of 7-d symptoms
score
54 (2010) 5e12 Prednisolone 1 mg/kg for 3e5
days, given within 6e8 h from
URI onset
Decrease Decrease Decrease NA
55 (2006) 0.1e3 Budesonide 400 mg qd  2 weeks
after 3 episodes wheezing since
1 mo old. Study period: 3 y
No decrease NA NA No effect Similar linear
growth to placebo
group
Persistent asthma
56 (2006) 4e11 Symbicort (80/4.5) as needed
use during URI period in patients
under regular budesonide
controller
Decreased Decreased NA NA Better symptom
score. Better
linear growth
than only regular
budesonide group.
57 (2011) <70 Fluticasone þ salmeterol or
Budesonide þ formoterol as
controller
No decrease No decrease NA No decrease A Cochrane
meta-analysis.
No decrease in
hospitalization
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86 L.-S. Fu, M.-C. Tsaiterms of asthma control, in a survey of 1003 patients in the
United States with uncontrolled asthma, 70% had an un-
scheduled visit to a physician’s office, 36% had an ED visit,
and 14% had a hospitalization in the last year. Even among
patients with controlled asthma, 43% had an unscheduled
visit to a physician’s office, 10% had an emergency
department visit, and 3% had a hospitalization in the pre-
vious year.8 Adequate management of persistent asthma
includes treatment with controller medications such as
inhaled corticosteroids (ICS) and leukotriene receptor an-
tagonists (LTRAs), which have been consistently shown to
reduce the risk of severe disease exacerbations.22,23 Poor
adherence to medicine is an important contributing factor
to poor asthma control. A recent study24 showed that
children with poor adherence to ICS had a 21% increase in
ED visits and a 70% increase in hospitalization.
4.2. Severe exacerbation in the previous year
One or more severe exacerbation(s) in the previous year
have been proven to be an independent risk factor for
future exacerbation.25e28 Asthmatic patients, especially
children,28 requiring an ED visit or hospitalization are at
significantly increased risk of future exacerbations inde-
pendent of demographic and clinical factors, asthma
severity, and asthma control.25 In a multivariate model,
recent severe exacerbation is the strongest predictor for
future severe exacerbation with an odds ratio (OR) of 3.08,
95% CIZ 2.21e4.28.27 Based on GINA guidelines,10 frequent
exacerbations in the past year is also a factor associated
with future risk.
4.3. Viruses
Viral infections have been implicated in most (>80%)
asthma exacerbations in children.29,30 Upper respiratory
tract viral infections have been recognized as a factor in
exacerbation events, particularly in children. Such in-
fections are sometimes referred to as the “September
epidemic” due to their seasonal pattern.31 Khetsuriani et al
conducted a study enrolling children 2e17 years of age
using a panel of PCR assays. Investigators compared chil-
dren experiencing an exacerbation with those who had
well-controlled asthma. Respiratory tract virus infection
was associated with exacerbation in 63.1% of the patients
compared with 23.4% in individuals with well-controlled
asthma (OR 5.6; 95% CI, 2.7e11.6).32 Although several vi-
ruses have been found in asthmatics, rhinovirus has been
the most commonly identified virus in proven viral-induced
asthma exacerbations in children aged 6e17 years (55%)
and in infants/pre-school children (33%). Other viruses
detected and associated with asthma exacerbation
included respiratory syncytial virus, enteroviruses, coro-
navirus, and human metapneumovirus.33
4.4. Allergen sensitization
Allergen sensitization, especially when there are more than
three allergen triggers, is also associated with asthma
exacerbation (OR 2.05, 95% CI Z 1.31e3.20).27 Simpson
et al34 observed that most children classified as atopic using
Asthma exacerbation in children 87conventional definitions were clustered into four distinct
classes: early multiple, late multiple, dust-mite, and non-
dust-mite. Only the early multiple class, which comprised
approximately a quarter of the atopic children, was
significantly associated with risk of hospitalization with
asthma. Because PRACTALL has proposed that a phenotype
of asthma is allergen-induced,16 which underscores the
heterogeneity in these disorders, a more detailed inter-
pretation of allergen sensitization may provide better
prediction of exacerbation.
4.5. Viruseallergen interactions
A growing body of evidence supports the view that viral
infection and allergy interact to increase the risk of an
exacerbation. Murray et al observed synergistic interaction
in children, which was even greater than the effect in
adults. In his study, neither sensitization to allergens nor
viral infection independently was associated with hospital
admittance. It was the combination of the presence of virus
and sensitization with high allergen exposure that
increased the risk of admission (OR 19.4, 3.5e101.5,
p < 0.001).35
4.6. Smoking
The relationship between second-hand smoke and asthma
morbidity in children is also well recognized. In the United
States, more than 200,000 episodes of childhood asthma
per year have been attributed to parental smoking.36
Mackay et al demonstrated a reduction of 18.2% per year
in the rate of asthma-related hospitalizations in children
after the implementation of a public smoking ban in Scot-
land. Before its implementation, asthma hospitalization
was increasing at a mean rate of 5.2% per year.37
4.7. Pollution
Acute exposure to specific pollutants contributes to symp-
toms and increases the severity of asthma exacerbations,
although their effects are not as pronounced as those of
viruses and aeroallergens.38 In children with asthma, NO2
exposure is associated with increased respiratory symp-
toms,39,40 and increased personal level of NO2 is associated
with increased severity of virus-induced exacerbations.41
4.8. Genes
Several single nucleotide polymorphisms (SNPs) are re-
ported to be related to asthma exacerbations. The T allele
of the IL-13 gene promoter SNP (rs1800925) was associated
with an increased risk of exacerbations among those
receiving ICS.42 Three low-affinity IgE receptor gene(FCεR2)
SNPs were significantly associated with elevated IgE level,
and each was associated with increased severe exacerba-
tions in white children.43 Racial differences must be taken
into consideration in gene studies. In Taiwan, Chen et al44
also reported a common variant of a gene coding for the
Cala cell 10 kDa protein to be a candidate determinant of
asthma severity and steroid response in Chinese asthmatic
children. More recently, Bisgaard et al, investigated genevariants associated with asthma and exacerbation in early
childhood. Variation at the 17q12-q21 locus was associated
with an approximately twofold increased risk of recurrent
wheeze, asthma exacerbations, and bronchial hyper-
reactivity from early infancy to school age, but without
conferring risk of eczema, rhinitis, or allergen sensitiza-
tion.45 This report adds to the growing evidence of genetic
variation in susceptibility to exacerbations, particularly in
non-atopic asthma, and further supports the existence of
an independent presence of exacerbations. Overall, the
finding that genetic variations affect severe exacerbation
demonstrates the need to consider the interaction of genes
with other known factors in the evaluation of children with
frequent exacerbations.
5. Strategies for Preventive Management
The preventive management of exacerbation can be
considered from two main perspectives in order to: (1)
decrease the severity of exacerbation, and (2) avoid future
exacerbation after the present attack. Here, we review
updated strategies to achieve these two aims in patients
with different conditions.
5.1. Intermittent asthma
Leukotriene receptor antagonist (LTRA) was reported to
reduce asthma exacerbation in patients with mild inter-
mittent asthma. A multi-center double-blind parallel group
study showed daily montelukast 4 or 5 mg for 12 months
significantly decreased the rate of exacerbation, the me-
dian time of first exacerbation, and the rate of inhaled
corticosteroid usage.23 An Australian randomized control
trial (RCT) conducted in children with mild intermittent
asthma, demonstrated that a short course of montelukast,
introduced by parents at the first signs of an asthma
episode for at least 7 days up to 48 hours after total
symptom resolution, resulted in a significant reduction in
acute health care resource utilization, symptoms, time off
from school, and parental time off from work.46 However,
there were no significant effects on hospitalization rate,
duration of symptoms, or use of bronchodilators and sys-
temic steroids. The effect on future exacerbation attacks
was not investigated in this study.
5.2. Intermittent wheezing in pre-school children
In pre-school age, the diagnosis of asthma is a difficult task,
and a long follow-up period is often required to define the
pattern of wheeze in young children. Nevertheless, during
the follow-up course, there are often severe wheezing at-
tacks that happen intermittently, especially when there is
respiratory tract infection. The PRACTALL consensus pro-
posed the concept of “virus-induced asthma” in which colds
are the most common precipitating factor, and which also
explains how some children can be completely well be-
tween symptomatic periods.16
Regarding the daily adherence and possible adverse ef-
fects of daily inhaled corticosteroid (ICS), several studies
have investigated the effects of intermittent therapy for
this phenotype in recent years and the results have been
88 L.-S. Fu, M.-C. Tsaiinstructive in pediatric clinical practice. For children aged
12e59 months with moderate to severe intermittent
wheezing, early use of budesonide inhalation or mon-
telukast in addition to albuterol for 7 days showed a modest
reduction in trouble breathing and interference of activity
compared with the placebo group, and the effects were
particularly significant in those with positive asthma pre-
dictive indices. The effects were comparable in these two
groups. However, neither episodic budesonide (1 mg twice
daily, via nebulizer), nor montelukast (4 mg daily) showed
differences in event-free days, oral corticosteroid use,
health care use, quality of life, or linear growth when
compared with the placebo group.47 Another study from
Canada48 enrolled children aged 1e6 years with at least 3
previous wheezing attacks and at least one moderate to
severe attack in the past 6 months in order to investigate
the pre-emptive use of inhaled fluticasone for virus-
induced wheezing. The study group received fluticasone
750 mg twice daily at the onset of upper respiratory infec-
tion and continued for a maximum of 10 days. In the 6e12-
month study period, the fluticasone group showed
decreased rescue systemic corticosteroid usage (OR 0.49,
95% CIZ 0.3e0.83), but they suffered from smaller gains in
height and weight. Therefore, its long-term benefits
require further clarification.
Zeiger et al compared intermittent and daily budesonide
therapy for preventing severe exacerbation in children
between the ages of 12 and 53 months who had positive
values on the modified API, recurrent wheezing episodes,
and at least one exacerbation in the previous year but a low
degree of impairment. Intermittent high-dose (1 mg)
budesonide given twice daily for 7 days, started early
during a predefined respiratory tract illness, showed a
comparable effect of daily budesonide (0.5 mg nightly) with
respect to the exacerbation frequency (0.95 vs. 0.97 per
patient year).49 There were also no significant between-
group differences in several other measures of asthma
severity, including the time to the first exacerbation, or
adverse events. The mean exposure to budesonide was
104 mg less with the intermittent regimen than with the
daily regimen. A meta-analysis from the Cochrane database
also addressed this issue in a study on the use of inhaled
steroids for episodic viral wheeze in childhood.50 It
concluded that episodic high-dose inhaled corticosteroids
provide a partially effective strategy for the treatment of
mild episodic viral wheeze in children. There is no current
evidence to favor maintenance of low-dose inhaled corti-
costeroids in the prevention and management of episodic
mild viral-induced wheeze.
The effects of early oral corticosteroid usage have also
been evaluated in recent years, but the results have been
inconsistent. For young children with previous wheezing
attack, a 5-day course of oral prednisolone (10 mg daily for
children aged between 10 and 20 months, 20 mg daily for
those between 20 and 60 months) was instituted on their
admission. Compared with the placebo group, there were
no differences in the duration of hospitalization, 7-day
symptom score, or albuterol usage.51 Another study of
children aged 5e12 years with a history of recurrent epi-
sodes of acute asthma used the strategy of parent-initiated
prednisolone when parents suspected imminent onset of a
severe asthma attack based on their previous experience orthe absence of improvement in symptoms within 6e8 hours.
Prednisolone 1 mg/kg/day was used for 3e5 days depending
on the persistence or resolution of their child’s asthma
symptoms. There was some reduction in asthma symptoms
(p Z 0.023), health resource use (p Z 0.01), and school
absenteeism (p Z 0.045).52 Overall, the present data sug-
gest that early institution of oral corticosteroid for pre-
vention of severe exacerbation is not recommended.
In an investigation of wheezing attack prevention, Bis-
gaard et al assigned infants to a treatment group with a 2-
week course of inhaled budesonide (400 mg/day), which
was initiated after a 3-day episode of wheezing, or to a
placebo group which received conventional care. There was
no decrease in the proportion of symptom-free days, per-
centage of persistent budesonide use, or acute episode
duration compared with the placebo group during the 3-
year follow-up, and there was no decrease in height or bone
mineral density in the study group.535.3. Persistent asthma
Controlled persistent asthma patients do have fewer ex-
acerbations than patients with uncontrolled persistent
asthma. However, even among controlled asthma patients,
43% have an unscheduled visit to a physician’s office, 11%
visit an ED, and 3% are hospitalized due to an exacerbation
each year.8 Therefore, an additional regimen before or in
the early stage of exacerbation is a recommended strategy
for better asthma control.
Bisgaard et al proposed symbicort maintenance and re-
lief therapy (SMART) as a new strategy in pediatric asthma
in 2006.54 SMART involves the use of symbicort 80/4.5 mg qd
plus additional doses as needed. In this 12-month, double-
blind, randomized study, 341 children aged 4e11 years
with uncontrolled asthma received regular ICS with an
average daily dosage up to budesonide 320 mg. SMART
showed 70% and 79% (p < 0.001) reductions in exacerbation
compared with groups receiving high-dose budesonide
(320 mg qd) þ terbutaline 0.4 mg as rescue and symbicort
80/4.5 mg qd þ terbutaline 0.4 mg as rescue, respectively.
The SMART regimen also reduced mild exacerbation days
and nighttime awakening. The yearly height growth was
better than that of the high-dose budesonide group. The
good result consequently led to several trials using the
SMART approach in several countries. In 2011, Cochrane
published a meta-analysis of combined fluticasone and
salmeterol versus fixed dose combination of budesonide
and formoterol for treatment of chronic asthma in adults
and children.55 In the present analysis, the SMART regimen
was not found to significantly decrease severe exacerba-
tions. The conclusion of this meta-analysis was that the
imprecise estimates of exacerbation indicate that further
research is warranted. Indeed, more recent studies on the
SMART regimen have yielded different results.
With regard to the safety of LABA usage in children,
guidelines in recent years recommend increasing ICS dosage
in uncontrolled asthma rather than adding LABA. The
SMART regimen was first proposed in 2006, before the
availability of guidelines specific for children, so even the
“maintenance” component of SMART is not the first choice
for children with persistent asthma.
Asthma exacerbation in children 89The development of mAbs directed against molecular
targets identified as important in patients with allergic
asthma has shown some early potential in preventing
asthma exacerbations. In a randomized trial of 6e12-year-
olds with multiple exacerbations despite ICS treatment, a
43% reduction in clinically significant exacerbations was
observed in the Omalizumab-treated group over a 1-year
period.56
To the best of our knowledge, a short course of
ICS þ LTRA combination for preventing pediatric asthma/
wheeze exacerbation has never been previously reported,
although ICSþLTRA was reported in a systemic review to be
superior to ICS alone for the prevention of future
exacerbation.576. Education and Comprehensive Follow-up
Plan
Aftercare of exacerbation events is a necessary component of
exacerbation care. Many physicians feel that families need to
be educated to recognize an imminent exacerbation and to
enhancecontrollermedication adherence.ACochrane review
published in 2009 found that educational programs signifi-
cantly reduced risk of subsequent ED visits and hospital ad-
missions, and also fewer unscheduled doctor visits compared
with controls. They concluded that asthma education aimed
at children (and their caregivers) who present to the ED for
acute exacerbations can result in lower risk of future ED
presentation and hospital admission.58 Schatz et al also
reviewed evidence of the effectiveness of follow-up after
acute asthma episodes.59 Recommendations based on their
findings are listed below: (1) telephone reminders of ap-
pointments should be used to improve the effectiveness of
patient follow-up after the ED visit, and if possible, appoint-
ments should be made before leaving the ED; (2) patients’
chronic severity should be characterized by items in asthma
guidelines; (3) specific elements should be included in the
follow-up visit, such as controller, inhaler technique, self-
monitoring, individualized asthma action plan, trigger iden-
tification, avoidance instruction, and further follow-up plans;
(4) patients should be referred to a specialist when indicated.7. Conclusion
One of the primary goals in the management of asthma is to
minimize the severity and future risk of exacerbations,
which also improves asthma control. Respiratory viruses are
now well accepted as the main trigger of these exacerba-
tions, and rhinoviruses remain the most commonly detec-
ted pathogens. The interaction of virus and sensitized
allergen in pediatric asthma/wheeze patients needs further
clarification, which should include the role of genetic
variation. At present, early episodic treatment modalities
provide some benefit, albeit to a limited extent, in
reducing the impact of exacerbation, but more research
needs to be done, especially with regard to identifying
subgroups of response. In our review of the literature it is
apparent that patients with previous severe exacerbation,
positive asthma predictive indices, and multiple allergen
sensitization require special attention and need to beeducated about these aspects of their disease. Pediatri-
cians must be capable of identifying the signs and symp-
toms of patients with chronic asthma so that families can
be educated to detect imminent exacerbation and adhere
to the asthma control plan. Referral to a pediatric allergy
specialist is indicated in pediatric patients with recurrent
exacerbations and persistent asthma.Conflicts of Interest
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